Background-Fabry disease is a treatable lysosomal storage disorder, which is often misdiagnosed or belatedly diagnosed. Methods and Results-To determine the disease incidence in the Taiwan Chinese population, a Fabry disease newborn screening study was initiated. A total of 110 027 newborns were screened by assaying the ␣-galactosidase A (␣-Gal A) activity using dry blood spots. Low plasma ␣-Gal A activity and presence of a Fabry mutation was demonstrated in 45 neonates (3 females). Eight different mutations were identified, including 3 known missense mutations (R112H, A143T, and R356W), 4 novel missense mutations (G104V, M296L, G360C, and K391T), and one known intronic mutation (IVS4ϩ919G3 A). The IVS4ϩ919G3 A mutation was most common (82% of patients). A total of 20 maternal grandparents of infants harboring this intronic mutation were evaluated by echocardiography, mutation analysis and ␣-Gal A activity assay. The intronic mutation was found in 9 grandfathers and 11 grandmothers. Of these grandparents, 3 grandfathers (33%) but none of the grandmothers had hypertrophic cardiomyopathy. Additionally, 16 males who had been diagnosed with idiopathic hypertrophic cardiomyopathy were screened by mutation analysis and ␣-Gal A activity; 4 (25%) showed deficient plasma ␣-Gal A activity in combination with the intronic mutation. Conclusion-We found an unexpected high prevalence of the cardiac variant Fabry mutation IVS4ϩ919G3 A among both newborns (Ϸ1 in 1600 males) and patients with idiopathic hypertrophic cardiomyopathy in the Taiwan 
F abry disease (MIM 301500) is an X-linked recessive lysosomal storage disorder resulting from deficient ␣-galactosidase A (␣-Gal A) activity. It has been estimated that this disease affects 1 in Ϸ50 000 males in the general population. 1,2 ␣-Gal A is an enzyme involved in the metabolic breakdown of globotriaosylceramide (GL-3) and deficient activity of this enzyme results in GL-3 accumulation in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes. It is a complex multisystemic disorder characterized clinically by peripheral neuropathic pains (chronic burning and acute episodes of severe pain), gastrointestinal disturbances, characteristic skin lesions (angiokeratomata), progressive renal impairment, cardiomyopathy, and early stroke. 1 
Clinical Perspective on p 456
In the past decades, 2 variant types of Fabry disease with manifestations primarily involving the heart 3-8 or kidneys 9, 10 have been reported, and several studies found that the Fabry cardiac variants usually mimic idiopathic hypertrophic car-diomyopathy (HCM). Patients with the cardiac variant lack the classical symptoms of Fabry disease and present in the 5th to 8th decades of life with left ventricular hypertrophy, arrhythmias, and/or cardiomyopathy. [3] [4] [5] [6] [7] [8] Previous studies have shown that 1% to 4% of male patients with left ventricular hypertrophy or HCM had undiagnosed Fabry disease. 6 -8 Enzyme replacement therapies (ERT) are available, and experiences to date indicate that early therapeutic intervention results in a better outcome. [11] [12] [13] [14] [15] Therefore, early detection of Fabry disease, especially of the variant types, is important. In the past decade, a new fluorimetric ␣-Gal A activity assay using dried blood spots (DBS) has been successfully developed and is a useful tool for Fabry disease screening initiatives. 16 -19 Spada et al 20 were the first to report the use of this assay in their Italian newborn screening program. This group found a higher than expected incidence of ␣-Gal A deficiency (1 in Ϸ3100 newborns) with a late-onset to classic type ratio of 11:1.
Our newborn screening study aimed at assessing the incidence of Fabry disease in the Taiwan Chinese population and is the largest Fabry screening study performed to date. In addition, our study aimed at identifying unrecognized Fabry patients among family members of diagnosed newborns and among individuals with idiopathic HCM.
Patients and Methods

Participants
The large-scale newborn screening program for Fabry disease was based on assessment of the ␣-Gal A enzyme activity using DBS on filter paper and was conducted at 2 newborn screening centers, the Chinese Foundation of Health and the Taipei Institute of Pathology, Taipei, Taiwan. The centers screen Ϸ55% of all newborns in Taiwan. Routine newborn screening DBS samples collected by the age of 3 days in 110 027 newborns between January 2008 and January 2009 were analyzed. Parental informed written consent was obtained for each sample collected. The study was approved by the ethics committee of the Taipei Veterans General Hospital, Taipei, Taiwan.
DBS Test
Alpha-Gal A activity in DBS on filter paper was determined using a fluorescence-based high-throughput method with modifications of a reported procedure. 16 To establish a normal population mean, ␣-Gal A activity was measured in 10,000 anonymous newborn samples. The normal mean of ␣-Gal A activity was 7.54Ϯ3.69 nmol/h/mL plasma. The activity of ␣-Gal A was rechecked if the newborns' ␣-Gal A activity was Ͻ3 mol/h/L (i.e. Ͻ40% of the normal mean). If the re-tested activity of ␣-Gal A was still Ͻ40%, "screen positive" was considered. For these individuals a second blood spot was requested and assayed. In the second blood spot, newborns with blood spot ␣-Gal A activities Ͻ2 mol/h/L (i.e. Ͻ25% of the normal mean) were considered "double DBS screen positive", and were recalled to Taipei Veterans General Hospital for confirmatory testing, including genetic analysis of the ␣-Gal A gene (Figure 1 ).
Plasma ␣-Gal A Enzyme Activity Assay
Plasma ␣-Gal A activity was determined using the substrate 4-methylumbelliferyl ␣-D-galactopyranoside (5 mmol/L) freshly prepared in 117 mmol/L N-acetyl-D-galactosamine/50 mmol/L citric-phosphate buffer, pH 4.6, before every assay. In brief, 50 L of plasma was mixed with 300 L of the substrate solution, incubated at 37°C for 2 hours, and 0.2 N glycine-NaOH was added to stop the reaction. Fluorescence intensity was measured with the excitation and emission wavelengths of 365 and 450 m, respectively. 21, 22 
␣-Gal A Gene Mutation Analysis
Patients with low ␣-Gal A enzyme activities (normal range: 7.9 to 16.9 nmol/h/mL plasma 21, 22 ) were subject to genetic analysis. Blood samples were obtained from these patients in blood collecting tubes containing ethylene diamine tetraacetic acid, and samples were stored at 4°C. DNA was isolated from whole blood using the GFX genomic Blood DNA Purification Kit (Amersham Biosciences, UK) following the manufacturer's instructions. The human ␣-Gal A gene consists of 7 exons. Each exon of ␣-Gal A gene was amplified by polymerase chain reaction using appropriate primers. 23 The polymerase chain reaction products were analyzed by 1.5% agarose I (Amresco) gel electrophoresis and then eluted in the polymerase chain reaction Advanced PCR Clean Up System (Viogene, USA.). Direct sequencing of the ␣-Gal A gene was processed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and ABI Prism 3730 Sequencer.
Pedigree Studies
For each patient, a complete pedigree was drawn and genetic counseling and pedigree analysis were provided to family members. Parents and grandparents of these patients were offered the combination of ␣-Gal A activity assay, mutation analysis, and related medical evaluations.
Screening of Patients With Idiopathic HCM in Cardiac Clinics
Twenty-three patients (16 men, 7 women; mean age 50.6Ϯ14.3 years; age range 18 to 67 years), who had been diagnosed with idiopathic HCM, were subject to analyses of plasma ␣-Gal A activity and the IVS4ϩ919G3 A mutation.
Results
Fabry Screening in Newborns
Of the 110 027 newborns screened, 57 451 (52.2%) were males and 52 576 (47.8%) females. There were 67 "double DBS screen positive" newborns (9 females) recalled to our hospital for confirmatory testing, of whom 45 newborns (3 females) were identified to have low plasma ␣-Gal A activity and a ␣-Gal A mutation (Table 1) . Eight mutations were detected, including 3 known missense mutations (R112H, 24, 25 A143T, 26, 27 and R356W 24, 28 ), 4 novel missense mutations (G104V, M296L, G360C, and K391T), and one known intronic splicing mutation (IVS4ϩ919G3 A 29 ; Table 2 ). None of these mutations were found in 50 unrelated healthy females. The IVS4ϩ919G3 A mutation was noted to be the most common mutation among these newborns (82% of patients). Although this splicing mutation has been found in Japanese Fabry patients with a cardiac variant, 29 its incidence in Japan is still unknown. In our study, the incidence of Fabry mutations was 1 in 1368 for males. If the 4 novel missense mutations were excluded, the incidence of the known diseasecausing mutations would be 1 in 1512 males.
Pedigree Studies
Data on enzyme activity levels and genetic analyses from the maternal grandparents was limited due to the unavailability of data, personal concerns or death. Among the 35 male neonates with the IVS4ϩ919G3 A mutation, 20 maternal grandparents were ascertained to have the same mutation, including 9 grandfathers and 11 grandmothers (Table 3) . Because of the high prevalence of the Fabry cardiac variant mutation IVS4ϩ919G3 A among the Taiwan Chinese population, we paid attention to the cardiac conditions of family members with the IVS4ϩ919G3 A mutation. Among 9 maternal grandfathers with the IVS4ϩ919G3 A mutation, 3 (33%) had HCM, compared with none of the 11 grandmothers with this disease (Table 3 ). The plasma ␣-Gal A activities of the 9 grandfathers ranged from 0.56 to 2.40 nmol/h/mL, whereas those of the 11 grandmothers ranged from 3.87 to 10.72 nmol/h/mL ( Table 3) .
Screening of Patients With Idiopathic HCM in Cardiac Clinics
To explore the occurrence of the cardiac variant mutation IVS4ϩ919G3 A in Taiwan Chinese idiopathic HCM patients, we analyzed the plasma ␣-Gal A activities and presence of this mutation in 23 patients diagnosed with HCM in the outpatient clinics. Four of 16 male patients (25%) had both deficient plasma ␣-Gal A activities (ranging from 0.65 to 0.98 nmol/h/mL) and the IVS4ϩ919G3 A mutation (Table 4). In contrast, the plasma ␣-Gal A activities in male patients without the IVS4ϩ919G3 A mutation ranged from 9.39 to 14.53 nmol/h/mL. It is noteworthy that none of the female patients was detected to have the IVS4ϩ919G/A mutation and that their plasma ␣-Gal A activities ranged from 6.59 to 16.12 nmol/h/mL.
Histologic examination of endomyocardial tissue of Patient 4 in Table 4 , a 67-year-old male patient with HCM, showed disorderly arranged myocytes with marked hypertrophy and large perinuclear and sarcoplasmic vacuoles, accompanied by focal interstitial fibrosis, which is consistent with the diagnosis of Fabry disease ( Figure 2 ).
Discussion
One of the important findings of our large-scale newborn screening study in the Taiwan Chinese population is the high incidence of Fabry mutations. The incidence of Fabry mutations was 1 in 1368 for males. This incidence is Ϸ30 times higher than previous estimates 1,2 and 2 times higher compared with the incidence found in an Italian newborn screening study. 20 Eight different mutations were identified, including 3 known missense mutations (R112H, 24, 25 A143T, 26, 27 and R356W 24, 28 ), 4 novel missense mutations (G104V, M296L, G360C, and K391T), and one known intronic mutation (IVS4ϩ919G3 A 29 ). The IVS4ϩ919G3 A mutation was most common (82% of patients). The 3 known mutations have been reported to be associated with mild classic (R356W 24, 28 ) or late-onset renal or cardiac (R112H, 24, 25 A143T 26, 27 ) forms. The intronic mutation (IVS4ϩ919G3 A) was reported to be a cardiac variant Fabry mutation. 29 None of the 4 novel mutations were found in 50 unrelated healthy females, which makes the possibility of polymorphisms unlikely. However, whether these mutations will eventually cause Fabry disease remains unknown. Further comprehensive family studies and long-term follow-up for identified individuals with these mutations are warranted. If the 4 novel missense mutations are excluded, the incidence of the known disease-causing mutations would be 1 in 1512 males.
In our study, only 1 newborn was noted to have a previously reported mutation (R356W) causing a classic phenotype. Therefore, the calculated incidence of classic Fabry disease in the Taiwan Chinese population is Ϸ1 in 57 000 males, which is equivalent to previous estimates. 1, 2 There was a surprisingly high incidence of the IVS4ϩ919G3 A mutation among newborns with ␣-Gal A deficiency. This intronic mutation was detected in 83.3% of the 42 male newborns found with Fabry mutations, which translates in an incidence of Ϸ1 in 1600 male newborns. This IVS4ϩ919G3 A mutation has been reported to be associated with cardiac variant Fabry disease by Ishii et al 29 It can activate an alternative splicing in intron 4 causing insertion of a 57-nucleotide sequence between exons 4 and 5 of the ␣-Gal A cDNA and subsequent premature termination after 7 altered amino acid residues downstream from exon 4. In general, the alternatively spliced transcript was present in a small amount (Ͻ5% of normal transcript) in most normal human tissues. However, in Fabry patients with the IVS4ϩ919G3 A mutation, the alternatively spliced transcript will be largely increased (Ͼ70% in lymphoblasts) and the enzyme activity will be decreased to Ͻ10% of normal activity (lymphoblast).
Another interesting finding of our study is that the mildform pathogenic mutation IVS4ϩ919G3 A apparently does not consistently cause Fabry-related HCM in all affected individuals. Of the 9 maternal grandfathers with the IVS4ϩ919G3 A mutation, only 3 had HCM. It remains to be elucidated why some patients with this mutation suffer from cardiomyopathy as early as in their 40s, whereas others with this same mutation do not have any symptoms or signs of cardiomyopathy even in their 70s. In this study, no correlation between the plasma ␣-Gal A activity and the existence of HCM was found. However, the sample size is too small to make definite conclusions regarding the likelihood of the IVS4ϩ919G3 A mutation leading to the cardiac variant of Fabry disease. Because the newborn screening is still ongoing, we hope that we will be able to eventually expand the database and get a clearer picture of this. Further investigations are required to identify genes or other factors involved in the modification of clinical expression of Fabry disease and to elucidate if there are other pathogenic mutations related to mild phenotypes.
Fabry disease has historically been described as an X-linked recessive disease, however, a substantial proportion of heterozygous females will develop disease manifestations. In some, the disease presentation may be as severe as seen in young males and others may remain relatively asymptomatic until late adulthood. 30, 31 This phenomenon is, in part, caused by skewed X chromosome inactivation. If most of the mutation-harboring X chromosomes are inactive in females, then the clinical presentation will be rather mild. On the other hand, the clinical presentation can be severe when most of the normal X chromosomes are inactive. With regard to cardiac involvement in female Fabry patients, Fabry disease may account for up to 12% of females with late-onset HCM. 32 Kampmann et al 33 evaluated 55 affected females and reported echocardiographic evidence of cardiac involvement in 56% of women younger than 38 years, in 86% of women older than 38 years, and in all female patients older than 45 years of age. Schiffmann et al 34 reported natural history data on 168 ERT-naive female Fabry patients of whom 35% had developed a cardiac event (eg, arrhythmia, angina, myocardial infarction, and cardiac surgery) by a mean age of Ϸ44 years. X-inactivation patterns vary widely between female Fabry patients and different tissues, and the enzyme activity measured in lymphocytes can be very different from other tissues, such as heart or kidney. Therefore, in females, the result of the lymphocyte enzyme activity assay is not predictive of disease severity in a particular organ, and the result may fall within the normal range although the female can be clinically affected. 35 Thus, the lymphocyte enzyme activity assay is not suitable as a screening tool in female populations, and it is not surprising that only a very few females were detected via the enzyme activity screening in this study. Screening for hot spot mutations may be an alternative method to detect unidentified female Fabry patients in high-risk populations.
Although only 1 ⁄3 of the grandfathers with the IVS4ϩ919G3A mutation had significant HCM, the high prevalence of this mutation in the Taiwan Chinese population points at an important presence of the cardiac variant of Fabry disease among patients with HCM in this particular population. Although the studied sample size of HCM is small and the Fabry screening in patients with HCM is still ongoing, we strongly recommend Table 4 ) showed markedly hypertrophic and disarrayed myocytes with large perinuclear and sarcoplasmic vacuoles (hematoxylin and eosin; ϫ400).
that Fabry disease must be ruled out before the diagnosis of idiopathic HCM is made in the Taiwan Chinese population, both in males and females.
There are few debates that early detection, genetic counseling, regular follow-up, and timely early therapeutic intervention for the classic Fabry disease is beneficial. However, for the individuals who have atypical Fabry mutations, particularly, for those whose residual enzyme activities are Ͼ10% to 20% of normal, the strategy for regular follow-up and therapeutic intervention should be different from those with the classic type, because our study showed that a significant proportion of the individuals older than 50 years of age with IVS4ϩ919G3 A mutation still have not developed any symptoms or signs of this disease. Therefore, the early detection of babies with atypical Fabry mutations results in several clinical impacts: When is the best time to start evaluating the cardiac conditions of these individuals with IVS4ϩ919G3 A mutation? When is the best time to start ERT? Do we need to start ERT early, when there are only controversial or minimal manifestations of heart problems? Or do we need to wait until the cardiac manifestations become marked? Several reports indicate that ERT for the advanced form of Fabry cardiomyopathy is not very effective. 12 Therefore, further investigations are needed to find out the best way for early detection of meaningful cardiac manifestations in patients with atypical Fabry mutations, and to identify the most appropriate time for them to start ERT.
In summary, this study in the Taiwan Chinese population demonstrates the feasibility of a large-scale neonatal screening program for Fabry disease. The incidence of Fabry mutations among newborns was unexpectedly high (Ϸ1 in 1400 male newborns), as was the prevalence of the cardiac variant mutation IVS4ϩ919G3 A. The diagnosis of Fabry disease should be considered in all patients with idiopathic HCM. The early identification of undiagnosed patients allows timely medical intervention providing a better clinical outcome.
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